Case Control Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 7, 2020; 26(5): 499-513
Published online Feb 7, 2020. doi: 10.3748/wjg.v26.i5.499
Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells
Hong Zheng, Jin-Jing Wang, Xiao-Rong Yang, Yong-Lin Yu
Hong Zheng, Jin-Jing Wang, Xiao-Rong Yang, Yong-Lin Yu, Department of Pathology, the Affiliated Hospital of Zunyi Medical University, Zunyi 563003, Guizhou Province, China
Author contributions: Zheng H designed the research; Wang JJ performed the research; Yang XR and Yu YL analyzed the data and wrote the paper.
Institutional review board statement: The study was approved by the Ethics Committee of the Affiliated Hospital of Zunyi Medical University (Guizhou, China).
Informed consent statement: All patients gave informed consent.
Conflict-of-interest statement: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Hong Zheng, PhD, Chief Physician, Department of Pathology, the Affiliated Hospital of Zunyi Medical University, No. 149, Dalian Road, Zunyi 563003, Guizhou Province, China.
Received: November 5, 2019
Peer-review started: November 5, 2019
First decision: December 7, 2019
Revised: December 13, 2019
Accepted: January 2, 2020
Article in press: January 3, 2020
Published online: February 7, 2020
Core Tip

Core tip: Gastric cancer (GC) is one of the most common types of cancer. The molecular mechanism of GC is intricate, and understanding the molecular mechanism of drug resistance is helpful for improving the efficacy of chemotherapy. The mutual binding of miRNAs and transcription factors is closely related to cancer occurrence. In this study, we found that E2F transcription factor 1 inhibited miR-34c transcription to both promote GC cell proliferation as well as enhance the resistance of paclitaxel combined with cisplatin. Therefore, silencing the expression of E2F transcription factor 1 in GC cells could improve the efficacy of paclitaxel combined with cisplatin.